MX2020009762A - Composicion farmaceutica que incluye alquil sulfato de sodio. - Google Patents
Composicion farmaceutica que incluye alquil sulfato de sodio.Info
- Publication number
- MX2020009762A MX2020009762A MX2020009762A MX2020009762A MX2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A MX 2020009762 A MX2020009762 A MX 2020009762A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- alkyl sulfate
- sodium alkyl
- composition including
- including sodium
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- -1 sodium alkyl sulfate Chemical class 0.000 title abstract 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000010828 elution Methods 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018051620 | 2018-03-19 | ||
| PCT/JP2019/011251 WO2019181876A1 (ja) | 2018-03-19 | 2019-03-18 | アルキル硫酸ナトリウムを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009762A true MX2020009762A (es) | 2021-01-08 |
Family
ID=67987327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009762A MX2020009762A (es) | 2018-03-19 | 2019-03-18 | Composicion farmaceutica que incluye alquil sulfato de sodio. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11833151B2 (enExample) |
| EP (3) | EP4353222A1 (enExample) |
| JP (2) | JP6918204B2 (enExample) |
| KR (1) | KR102473372B1 (enExample) |
| CN (1) | CN111867594A (enExample) |
| AU (1) | AU2019239404B2 (enExample) |
| BR (1) | BR112020018697A2 (enExample) |
| CA (1) | CA3094431C (enExample) |
| DK (1) | DK3769765T3 (enExample) |
| ES (1) | ES2980333T3 (enExample) |
| FI (1) | FI3769765T3 (enExample) |
| HU (1) | HUE067430T2 (enExample) |
| MA (1) | MA52093A (enExample) |
| MX (1) | MX2020009762A (enExample) |
| MY (1) | MY203305A (enExample) |
| PH (1) | PH12020551412A1 (enExample) |
| PL (1) | PL3769765T3 (enExample) |
| PT (1) | PT3769765T (enExample) |
| RU (1) | RU2759746C1 (enExample) |
| SG (1) | SG11202008435SA (enExample) |
| TW (1) | TWI790364B (enExample) |
| WO (1) | WO2019181876A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102793563B1 (ko) | 2016-03-04 | 2025-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP4353222A1 (en) * | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Use of sodium alkyl sulfate |
| WO2020110974A1 (ja) * | 2018-11-26 | 2020-06-04 | 大鵬薬品工業株式会社 | 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法 |
| WO2023238929A1 (ja) * | 2022-06-10 | 2023-12-14 | 大鵬薬品工業株式会社 | ピミテスピブを含有する医薬組成物 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3433239A1 (de) * | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
| FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| WO1998047499A1 (en) * | 1997-04-22 | 1998-10-29 | Nippon Kayaku Kabushiki Kaisha | Flutamide preparations and method for manufacturing the same |
| JP4117811B2 (ja) * | 1997-04-22 | 2008-07-16 | 日本化薬株式会社 | フルタミド製剤及びその製法 |
| NZ328751A (en) * | 1997-09-16 | 1999-01-28 | Bernard Charles Sherman | Solid medicament containing an anionic surfactant and cyclosporin |
| NZ524120A (en) | 2000-07-19 | 2005-08-26 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| PL401638A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
| ATE495155T1 (de) | 2003-11-19 | 2011-01-15 | Array Biopharma Inc | Heterocyclische inhibitoren von mek |
| DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
| RU2364596C2 (ru) | 2004-06-11 | 2009-08-20 | Джапан Тобакко Инк. | ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ |
| CA2582247C (en) | 2004-10-20 | 2014-02-11 | Applied Research Systems Ars Holding N.V. | 3-arylamino pyridine derivatives |
| AU2006257273A1 (en) * | 2005-06-17 | 2006-12-21 | Pfizer Inc. | Alpha-(ARyl-Or heteroaryl-methyl)-beta-piperidinopropanoic acid compounds as orl1-receptor antagonists |
| ES2481402T3 (es) | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
| US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| DE602006009968D1 (de) | 2005-11-15 | 2009-12-03 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| US7659274B2 (en) | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| MX2008013675A (es) | 2006-04-26 | 2009-03-06 | Supernus Pharmaceuticals Inc | Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal. |
| EP1939197A1 (en) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| NZ579911A (en) | 2007-03-28 | 2012-05-25 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
| DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
| PL2203181T3 (pl) | 2007-10-16 | 2018-07-31 | Biocon Limited | Podawana doustnie stała kompozycja farmaceutyczna i jej sposób |
| CN102123989A (zh) | 2008-06-19 | 2011-07-13 | 阿斯利康(瑞典)有限公司 | 吡唑化合物436 |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| EA020017B1 (ru) | 2009-04-30 | 2014-08-29 | Новартис Аг | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ |
| KR101483215B1 (ko) | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| WO2011115937A1 (en) | 2010-03-14 | 2011-09-22 | The Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| DE102011015188A1 (de) | 2010-03-29 | 2011-09-29 | Herbert Kannegiesser Gmbh | Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen |
| WO2011122620A1 (ja) * | 2010-03-29 | 2011-10-06 | 味の素株式会社 | フェニルアラニン誘導体を含有する医薬製剤 |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| AR083417A1 (es) | 2010-10-14 | 2013-02-21 | Novartis Ag | Composiciones farmaceuticas que contienen un dgat1 inhibidor |
| TWI525097B (zh) | 2011-04-06 | 2016-03-11 | Taiho Pharmaceutical Co Ltd | Novel imidazole and A compound or a salt thereof |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| EP2657233B1 (en) | 2012-01-19 | 2014-08-27 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| JP2015505562A (ja) | 2012-01-31 | 2015-02-23 | ノバルティス アーゲー | Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用 |
| CA2865021C (en) | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| RU2618423C2 (ru) | 2012-07-02 | 2017-05-03 | Тайхо Фармасьютикал Ко., Лтд. | Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| BR112015012051A2 (pt) | 2012-11-26 | 2017-12-12 | Roche Innovation Ct Copenhagen As | composições e métodos para modulação de expressão de fgfr3 |
| CN105246511A (zh) | 2013-03-06 | 2016-01-13 | 豪夫迈·罗氏有限公司 | 治疗和预防癌症药物抗性的方法 |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| PL3012327T3 (pl) | 2013-06-20 | 2021-04-19 | Taiho Pharmaceutical Co., Ltd. | Sposób przewidywania skuteczności terapeutycznej inhibitora PI3K/AKT/mTOR na podstawie ekspresji PHLDA1 lub PIK3C2B |
| EP3023100B1 (en) | 2013-07-18 | 2019-03-13 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of fgfr inhibitor |
| TW201536293A (zh) | 2013-07-18 | 2015-10-01 | Taiho Pharmaceutical Co Ltd | 對ｆｇｆｒ抑制劑具耐受性之癌的治療藥 |
| WO2015150900A2 (en) * | 2014-03-31 | 2015-10-08 | Debiopharm International Sa | Fgfr fusions |
| EP4397659A3 (en) | 2014-04-25 | 2024-10-02 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| US10481946B2 (en) * | 2014-05-12 | 2019-11-19 | Hitachi, Ltd. | Information-processing device, processing method thereof, and input/output device |
| AU2015327868A1 (en) | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| MA41350A (fr) | 2015-01-14 | 2017-11-21 | Janssen Pharmaceutica Nv | Synthèse d'un inhibiteur de la tyrosine kinase de bruton |
| CN105859721B (zh) | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| CN112494653A (zh) | 2015-02-05 | 2021-03-16 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| WO2016130917A1 (en) | 2015-02-12 | 2016-08-18 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| JPWO2016136928A1 (ja) | 2015-02-27 | 2017-08-31 | 大鵬薬品工業株式会社 | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 |
| PT3279202T (pt) | 2015-03-31 | 2020-08-31 | Taiho Pharmaceutical Co Ltd | Cristal de composto de alquinilo de benzeno 3,5-dissubstituído |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| AU2016286091B2 (en) | 2015-06-29 | 2021-02-04 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| EP3120851A1 (en) * | 2015-07-21 | 2017-01-25 | Pangaea Biotech S.L. | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers |
| JP2018524010A (ja) * | 2015-07-24 | 2018-08-30 | デバイオファーム インターナショナル エスエイ | Ｆｇｆｒ発現とｆｇｆｒ阻害剤に対する感受性 |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| JP6860919B2 (ja) | 2015-11-19 | 2021-04-21 | 国立大学法人金沢大学 | 間葉系ｋｒａｓ変異型がん治療剤 |
| KR102793563B1 (ko) | 2016-03-04 | 2025-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| JP2018002662A (ja) | 2016-07-01 | 2018-01-11 | 大鵬薬品工業株式会社 | キノリルピロロピリミジル縮合環化合物を合成するために有用な中間体 |
| JP6296308B1 (ja) | 2016-09-26 | 2018-03-20 | ツジカワ株式会社 | ロール装置 |
| JP7503380B2 (ja) | 2017-01-10 | 2024-06-20 | ノバルティス アーゲー | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 |
| EP4353222A1 (en) * | 2018-03-19 | 2024-04-17 | Taiho Pharmaceutical Co., Ltd. | Use of sodium alkyl sulfate |
| US20210387990A1 (en) | 2018-11-09 | 2021-12-16 | Taiho Pharmaceutical Co., Ltd. | Method for producing dimethoxybenzene compound |
| KR102742083B1 (ko) | 2018-11-09 | 2024-12-16 | 다이호야쿠힌고교 가부시키가이샤 | 디메톡시벤젠 화합물의 제조 방법 |
| WO2020110974A1 (ja) | 2018-11-26 | 2020-06-04 | 大鵬薬品工業株式会社 | 線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法 |
| WO2020170355A1 (ja) | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| EP3932427A4 (en) | 2019-02-28 | 2022-12-07 | Taiho Pharmaceutical Co., Ltd. | CANCER THERAPY USING A 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND AND PEMBROLIZUMAB |
| MA56549A (fr) | 2019-06-21 | 2022-04-27 | Taiho Pharmaceutical Co Ltd | Méthode de traitement d'une tumeur maligne |
-
2019
- 2019-03-18 EP EP24160537.7A patent/EP4353222A1/en not_active Withdrawn
- 2019-03-18 PT PT197719982T patent/PT3769765T/pt unknown
- 2019-03-18 KR KR1020207029418A patent/KR102473372B1/ko active Active
- 2019-03-18 MA MA052093A patent/MA52093A/fr unknown
- 2019-03-18 US US16/982,377 patent/US11833151B2/en active Active
- 2019-03-18 SG SG11202008435SA patent/SG11202008435SA/en unknown
- 2019-03-18 RU RU2020133810A patent/RU2759746C1/ru active
- 2019-03-18 CN CN201980020022.5A patent/CN111867594A/zh active Pending
- 2019-03-18 EP EP19771998.2A patent/EP3769765B1/en active Active
- 2019-03-18 CA CA3094431A patent/CA3094431C/en active Active
- 2019-03-18 EP EP24207166.0A patent/EP4470621A3/en active Pending
- 2019-03-18 PL PL19771998.2T patent/PL3769765T3/pl unknown
- 2019-03-18 AU AU2019239404A patent/AU2019239404B2/en active Active
- 2019-03-18 FI FIEP19771998.2T patent/FI3769765T3/fi active
- 2019-03-18 ES ES19771998T patent/ES2980333T3/es active Active
- 2019-03-18 MY MYPI2020004844A patent/MY203305A/en unknown
- 2019-03-18 JP JP2020507802A patent/JP6918204B2/ja active Active
- 2019-03-18 TW TW108109195A patent/TWI790364B/zh active
- 2019-03-18 MX MX2020009762A patent/MX2020009762A/es unknown
- 2019-03-18 DK DK19771998.2T patent/DK3769765T3/da active
- 2019-03-18 HU HUE19771998A patent/HUE067430T2/hu unknown
- 2019-03-18 WO PCT/JP2019/011251 patent/WO2019181876A1/ja not_active Ceased
- 2019-03-18 BR BR112020018697-0A patent/BR112020018697A2/pt unknown
-
2020
- 2020-09-09 PH PH12020551412A patent/PH12020551412A1/en unknown
-
2021
- 2021-07-19 JP JP2021118771A patent/JP7322103B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551412A1 (en) | Pharmaceutical composition including sodium alkyl sulfate | |
| CL2018003604A1 (es) | Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983) | |
| MX2022007968A (es) | Dosificacion de gamma-hidroxibutirato (ghb). | |
| MX2025003876A (es) | Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| EA201290131A1 (ru) | Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| BRPI0610108B8 (pt) | compostos promotores de apoptose e composição que compreende os ditos compostos | |
| BR112014017716A8 (pt) | composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol | |
| TNSN07005A1 (fr) | Analogues tetrapeptidiques | |
| CL2008001756A1 (es) | Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac) | |
| BR112014005617A2 (pt) | tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv | |
| CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
| PH12019550249A1 (en) | Solid compositions for oral administration | |
| GEP20247648B (en) | 4h-pyrrolo[3,2-c]pyridin-4-one compounds | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| BR112016004358A8 (pt) | combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit | |
| PH12022551468A1 (en) | Compounds active towards nuclear receptors | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| BRPI0017528B8 (pt) | uso de uma composição contendo sal de cetotifeno | |
| WO2020097568A3 (en) | Oligosaccharide compositions and methods of use thereof | |
| AR112448A1 (es) | Derivados de xantina sustituidos | |
| MX2020004397A (es) | Uso de suplementos de aminoacidos para mejorar la sintesis de proteinas musculares. |